Navigation Links
Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
Date:5/16/2008

HOUSTON - Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center.

These findings are surprising and represent the first positive study for Iressa in breast cancer, as well as for the entire class of drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M.D., the study's principal investigator.

Cristofanilli will present the findings at the American Society for Clinical Oncology's (ASCO) upcoming annual meeting as an oral presentation.

"We initiated this study in 2003 with hopes of reducing the resistance to hormonal therapy," said Cristofanilli. "There was a lot of preclinical work indicating that, in fact, resistance to hormonal therapy is strongly associated with an activated EGFR pathway. Also, EGFR over-expression has been associated with endocrine resistance. If there's a double blockage of the EGFR and the estrogen receptor, you may achieve better control of the disease."

The Phase II study enrolled 93 women from 30 centers across the United States and Latin America, with M. D. Anderson enrolling 20 patients. All of the women were newly diagnosed with metastatic breast cancer and were hormone receptor positive and estrogen receptor HER-2 negative. Patients were randomized to receive the aromatase inhibitor Arimidex (1 milligram) and Iressa (250 milligram) daily or Arimidex and placebo. The primary endpoint was progression-free survival.

When the study was unblinded, the researchers were surprised by the distinct findings: in the women who received Arimidex and Iressa, progression-free survival was 14.5 months, compared to 8.2 months in the women who did not rece
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
2. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
3. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
4. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
5. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
6. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
7. Research shows HPV testing offers women protection for twice as long as smear testing
8. Study shows that prostate cancer increases the risk of bone fracture
9. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
10. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
11. Expanded food and nutrition program shows $10 benefit for each $1 spent
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... allows users to clarify, edit and delete any message including ones already sent. , ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . ... which are customizable. The best part: whenever a product is purchased, the Meso ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Growth Initiatives, ROCHESTER, N.Y., Sept. 17 ... completed a private placement of,$4,350,000 of Series B ... institutional and other accredited investors. VirtualScopics,currently intends to ... expand its,sales and marketing efforts, software and technology ...
... Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that Edward F. Brennan, President and Chief,Executive Officer, and ... at the Maxim Group First Annual Growth Conference in,New ... a.m. ET at The Grand,Hyatt Hotel. A live ...
... St. Margaret,s Daughters, Home, NEW ORLEANS, Sept. 17 ... New Orleans will be reunited in a,temporary facility this ... Hurricane Katrina. The 116-bed eldercare facility was destroyed ... Ninth Ward. While everyone at St.,Margaret,s was evacuated safely ...
... John Brooke, General Manager of,Billian,s HealthDATA, leading provider ... ,07 Global Gathering, Salesforce.com,s 5th,Annual User and Developer ... is the ultimate gathering of the salesforce.com community,bringing ... and AppExchance,users spanning industries, roles and locales. Mr. ...
... time scientists have been able to film, in real ... DNA strand from an attacking virus. Researchers from the ... Force Microscope in Japan to produce amazing footage of ... trying to infect a bacterial host. , The ...
... may only be modestly accurate, according to researchers from the ... Carolina. In a study that appears in the October issue ... usefulness of a scale that asks patients in primary care ... 10 (worst pain). , Universal pain screening is ...
Cached Medicine News:Health News:VirtualScopics Announces $4.35 Million Private Placement 2Health News:VirtualScopics Announces $4.35 Million Private Placement 3Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Renovated New Orleans Care Facility Reopens, Reuniting Residents and Staff 2Health News:Renovated New Orleans Care Facility Reopens, Reuniting Residents and Staff 3Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Scientists reveal DNA-enzyme interaction with first ever real time footage 2Health News:Rating your pain from 0 to 10 might not help your doctor 2
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced the ... of Warburg Pincus LLC, to the Amgen Board of Directors. ... Hassan and the deep, global experience he brings in ... A. Bradway , chairman and chief executive officer of Amgen. "Fred,s ... Amgen well." Mr. Hassan has been Partner and ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... YORK, Jan. 13, 2011 Reportlinker.com announces that ... its catalogue: Merck & Co., ... IntroductionThis analysis examines the ... in the prescription pharmaceutical sector. The profile encompasses ...
... Codexis, Inc. (Nasdaq: CDXS) today announced the company will host ... at 4:30 p.m. Eastern Time to discuss its fourth quarter ... call and webcast will follow the release of fourth quarter ... call will be available approximately one hour after the call ...
Cached Medicine Technology:Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
Simply stated, no bone cement can match the history of Simplex™. Simplex™ is the only cement with 40 years of proven clinical performance - trusted by tens of thousands of surgeons with o...
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... John Charnley and CMW, Inc. began ... bone cements exclusively for orthopaedic applications. ... years of performance and excellence in ... one of the first proven bone ...
... Paradigm's Dicon Ocular Blood Flow Analyzer is ... increase your early diagnosis of low and ... (BFA) provides a fast, clinically proven measurement ... BFA assists in the management of glaucoma, ...
Medicine Products: